text stringlengths 1 711 |
|---|
35% |
Advertising % of Sales Average Median |
Source: Company reports and J.P. Morgan estimates. |
This document is being provided for the exclusive use of DAVID WANG at MARLOWE PARTNERS LP. |
29 |
Andrea Teixeira, CFA AC |
(1-212) 622-6735 |
andrea.f.teixeira@jpmorgan.com |
North America Equity Research |
29 May 2023 J P M O R G A N |
R&D Is Higher Than Peers |
On the other hand, KVUEs R&D spending is in the top quartile vs. peers at 2.5% |
(average 2.0% and median 1.8%), which speaks to the companys commitment to |
spending behind developing innovation and driving unique claims for its products. |
Figure 43: Research and Development Expense vs. Peers |
CY22 or Last Fiscal* where noted |
0.0% |
0.5% |
1.0% |
1.5% |
2.0% |
2.5% |
3.0% |
3.5% |
R&D % of Sales Average Median |
Source: Company reports and J.P. Morgan estimates. |
Longer term, KVUEs financial algorithm calls for earnings growth ahead of sales |
growth, although given the burden of stand-alone company costs and incremental |
interest expense, earnings per share growth will likely fall below this target in 2023 and |
2024 before seeing faster growth in 2025 as the company sees leverage throughout the |
P&L for the aforementioned reasons. From an EBITDA perspective, however, we do see |
KVUE generating profit growth ahead of sales growth from 2023-2025 with a threeyear |
CAGR of +6.1% vs. top-line CAGR of +4.3%, implying EBITDA margin |
expansion to 25.4% in 2025 from 24.1% in 2022 (roughly +130 bps expansion) and |
25.3% in 2021. |
Figure 44: KVUE EBITDA Growth Outlook |
21.7% |
0.9% |
-5.4% |
5.3% 4.9% |
8.2% |
$3,101 |
$3,775 $3,810 $3,606 $3,797 $3,983 |
$4,308 |
-10% |
-5% |
0% |
5% |
10% |
15% |
20% |
25% |
$0 |
$500 |
$1,000 |
$1,500 |
$2,000 |
$2,500 |
$3,000 |
$3,500 |
$4,000 |
$4,500 |
$5,000 |
2019 2020 2021 2022 2023E 2024E 2025E |
EBITDA $ m (left-axis) EBITDA YOY Growth (right-axis) |
Source: Company reports and J.P. Morgan estimates. |
Figure 45: KVUE EBITDA vs. Sales Growth Outlook |
6.1% |
4.3% |
0% |
1% |
2% |
3% |
4% |
5% |
6% |
7% |
EBITDA CAGR (2023-2025) Sales CAGR (2023-2025) |
Source: J.P. Morgan estimates. |
For ease of comparison, we prefer to look at EBITDA as the primary profit KPI for |
KVUE as the companys adjusted earnings per share excludes the impact of |
amortization of definite life intangible assets, which it treats 100% of brands/ |
trademarks, while competitors do not adjust this expense out. As such, KVUEs adjusted |
earnings appear higher than they otherwise would following the accounting convention |
across our coverage universe. In our model we present adjusted earnings per share both |
with and without the impact of amortization of intangible assets, but we think investors |
This document is being provided for the exclusive use of DAVID WANG at MARLOWE PARTNERS LP. |
30 |
Andrea Teixeira, CFA AC |
(1-212) 622-6735 |
andrea.f.teixeira@jpmorgan.com |
North America Equity Research |
29 May 2023 J P M O R G A N |
may prefer to look to EBITDA. |
Versus the peer set, KVUEs EBITDA margins are in the top quartile at 24.1% vs. |
average 21.3% and median 21.8% (ex-OLPX average 18.8% and median 20.9%), but |
still trail closest peer HLN (25.1%), and are between PG (25.0%) and CL (23.5%). We |
see opportunity for KVUE to expand EBITDA margins ahead as pricing flows through, |
inflation abates, and the company works to take out costs to stand up the company (e.g., |
TSA, TMA). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.